The NeurologyLive® stroke clinical focus page serves as a resource for updates and information related to the clinical care and management of stroke and cerebrovascular disease, featuring news, podcasts, and videos about the latest FDA actions, clinical guideline updates, interviews with physicians, and study and clinical trial findings. The page includes information on stroke, large vessel occlusion, subcranial hemorrhage, intracranial hemorrhage, ischemic stroke, and more.
Check out some of NeurologyLive®'s featured content in the carousel below.
January 30th 2023
Here's some of what is coming soon to NeurologyLive® this week.
Ticagrelor and Aspirin Combination Most Effective in CYP2C19 Carriers With Low Risk Profile
January 19th 2023The study provided class II evidence that CYP2C19 loss of function carriers with minor stroke or transient ischemic attack at low risk, but not high risk, of recurrent stroke received greater benefit from ticagrelor and aspirin rather than clopidogrel and aspirin.
Clinicians Raise Concerns Over Lecanemab Following Patient Death Treated With tPA for Stroke
January 5th 2023In the phase 3 Clarity AD trial, a 65-year-old patient treated with lecanemab died because of multiple cerebral hemorrhages after undergoing tissue plasminogen activator therapy for ischemic stroke.
FDA Approves Insightec’s Exablate Neuro to Treat Second Side of Essential Tremor
December 21st 2022Using focused ultrasound waves, the Exablate Neuro platform has now gained the FDA greenlight for medication-refractory essential tremor, tremor-dominant Parkinson disease, and second side of essential tremor.
COVID-19 and the Brain: Understanding the Neurological Effects of the Virus as the Pandemic Evolves
December 16th 2022Almost 3 years since the beginning of the pandemic, continuous research efforts have begun to paint a better picture of the impact the virus has on the brain and the central nervous system.
Building the Biomarker Panel in Neurology: Glial Fibrillary Acidic Protein
December 9th 2022As the treatment paradigm for neurologic diseases rapidly progresses, the need for more thorough biomarker tools to measure disease progression and severity has increased, and in recent years, GFAP has emerged as a valuable candidate to add to the existing panel.